Mandibulofacial dysostosis with microcephaly

Mendelian MONDO:0012516 Pathograph 23 Show in embeddings browser hereditary disease

Mandibulofacial dysostosis with microcephaly (MFDM; Guion-Almeida type) is a rare autosomal dominant multiple congenital anomaly syndrome caused by de novo haploinsufficiency of EFTUD2, the gene encoding U5-116kD/SNU114, a core GTPase of the U5 small nuclear ribonucleoprotein (snRNP) of the major spliceosome. It is characterized by malar and mandibular hypoplasia, microcephaly (congenital or postnatal), external ear malformations (microtia) with conductive and/or sensorineural hearing loss, cleft palate, choanal atresia, esophageal atresia/tracheoesophageal fistula, congenital heart defects, thumb/radial-ray anomalies, and developmental delay with intellectual disability. MFDM was the first multiple-malformation syndrome attributed to a defect of the major spliceosome.

Ask OpenScientist

Ask a research question about Mandibulofacial dysostosis with microcephaly. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
3
Pathophys.
19
Phenotypes
23
Pathograph
1
Genes
5
Medical Actions
1
References
1
Deep Research
👪

Inheritance

1
Autosomal dominant inheritance HP:0000006
MFDM is an autosomal dominant disorder. Most affected individuals have a de novo heterozygous loss-of-function variant in EFTUD2; in a minority the variant is inherited from a mildly affected parent.
Autosomal dominant inheritance
Show evidence (2 references)
PMID:24999515 SUPPORT Other
"MFDM is an autosomal dominant disorder. Most individuals diagnosed with MFDM to date are presumed to have the disorder as the result of a de novo EFTUD2 pathogenic variant; in some individuals, the causative pathogenic variant was inherited from a parent with a milder phenotypic presentation."
GeneReviews directly states the autosomal dominant, predominantly de novo inheritance of MFDM.
PMID:33247512 SUPPORT Human Clinical
"Targeted Sanger sequencing for families of seven individuals demonstrated de novo variants, for a total of 91.9% de novo EFTUD2 variants (n = 34/37)."
A large patient cohort confirms that the great majority of EFTUD2 variants causing MFDM arise de novo.
⚙

Pathophysiology

3
EFTUD2 haploinsufficiency impairs U5 snRNP spliceosome function
MFDM is caused by heterozygous loss-of-function variants (null alleles, frameshifts, intragenic and contiguous 17q21.31 deletions, and a subset of missense and splice-altering variants) in EFTUD2. EFTUD2 encodes U5-116kD (SNU114), a highly conserved spliceosomal GTPase that is a core component of the U5 snRNP with a central regulatory role in catalytic pre-mRNA splicing and post-splicing spliceosome disassembly. Reduced EFTUD2 dosage impairs the major spliceosome, making MFDM the first multiple-malformation syndrome attributed to a defect of the major spliceosome.
EFTUD2 hgnc:30858 ↓ DECREASED
mRNA splicing via the major spliceosome GO:0000398 ⚠ ABNORMAL
U5 snRNP GO:0005682
Downstream
Disrupted pre-mRNA splicing in neural crest and craniofacial development Impaired U5 snRNP/spliceosome function reduces fidelity and efficiency of pre-mRNA splicing during embryogenesis, including in cranial neural crest derivatives.
Mdm2 mis-splicing activates p53-dependent neural crest apoptosis Impaired spliceosome function increases exon skipping, including mis-splicing of Mdm2, coupling the core splicing defect to P53-pathway activation.
Show evidence (3 references)
PMID:22305528 SUPPORT Human Clinical
"A range of EFTUD2-mutation types, including null alleles and frameshifts, is seen in MFDM, consistent with haploinsufficiency; segregation is de novo in all cases assessed to date. U5-116kD, the protein encoded by EFTUD2, is a highly conserved spliceosomal GTPase with a central regulatory role..."
The original gene-discovery paper establishes EFTUD2 haploinsufficiency and the role of U5-116kD as a core spliceosomal GTPase.
PMID:22305528 SUPPORT Human Clinical
"MFDM is the first multiple-malformation syndrome attributed to a defect of the major spliceosome."
Supports the classification of MFDM as a major-spliceosome disorder.
PMID:32333448 SUPPORT In Vitro
"Pathogenic variants in the core spliceosome U5 small nuclear ribonucleoprotein gene EFTUD2/SNU114 cause the craniofacial disorder mandibulofacial dysostosis Guion-Almeida type (MFDGA)."
Functional yeast and minigene assays confirm EFTUD2 as a core U5 snRNP gene whose variants cause MFDGA by loss-of-function.
Disrupted pre-mRNA splicing in neural crest and craniofacial development
The major spliceosome is broadly required for pre-mRNA maturation during embryogenesis, including in cranial neural crest cells that give rise to craniofacial skeletal and connective tissues. Insufficient EFTUD2 dosage disrupts splicing-dependent gene expression during neural crest and craniofacial morphogenesis, contributing to malar/mandibular hypoplasia, ear and palatal malformations, and brain underdevelopment. A zebrafish eftud2-null model shows reduced head size, small eye, and widespread apoptosis in the developing brain, eye, and spinal cord, demonstrating a conserved requirement during development of diverse tissues.
migratory neural crest cell CL:0000333
mRNA splicing via the major spliceosome GO:0000398 ⚠ ABNORMAL
Downstream
Malar hypoplasia Disrupted splicing-dependent gene expression in cranial neural crest derivatives impairs midface (malar/zygomatic) skeletal development.
Mandibular hypoplasia (micrognathia) Disrupted neural crest-derived first pharyngeal arch development impairs mandibular growth.
Microcephaly Disrupted splicing-dependent gene expression and increased apoptosis in the developing brain contribute to reduced brain growth and microcephaly.
External ear malformation (microtia)
Conductive hearing loss
Sensorineural hearing loss
Choanal atresia
Cleft palate
Esophageal atresia / tracheoesophageal fistula
Tracheoesophageal fistula
Congenital heart defect
Thumb anomaly
Intellectual disability
Developmental delay
Speech and language delay
Seizures
Short stature
Spine anomalies
Facial asymmetry
Show evidence (2 references)
PMID:23188108 SUPPORT Human Clinical
"emphasise the necessity of mRNA maturation through the spliceosome complex for global growth and within specific regions of the embryo during development."
Supports the requirement of spliceosome-dependent mRNA maturation for normal embryonic growth and regional development.
PMID:26118977 SUPPORT Model Organism
"Homozygous mutants displayed a reduced head size, small eye, curved body, and early embryonic lethality. Apoptosis assays demonstrated a striking increase in terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL)-positive cells in the developing brain,..."
The zebrafish eftud2 model recapitulates reduced head size and shows developmental apoptosis, supporting a conserved role of EFTUD2 in craniofacial and neural development.
Mdm2 mis-splicing activates p53-dependent neural crest apoptosis
In vertebrate models of EFTUD2 deficiency, the splicing defect causes increased exon skipping, including an alternatively spliced Mdm2 transcript lacking exon 3. Reduced functional MDM2 stabilizes and activates nuclear P53, increasing expression of P53-target genes and triggering apoptosis of cranial neural crest cells and neural progenitors. Early depletion of these craniofacial precursor populations drives the craniofacial malformations and microcephaly of MFDM. The mechanism is partly p53-dependent: pharmacologic P53 inhibition (pifithrin-alpha) partially rescues craniofacial development, while Trp53 deletion reduces apoptosis without fully rescuing morphology, implying additional p53-independent mis-splicing contributions.
migratory neural crest cell CL:0000333
signal transduction by p53 class mediator GO:0072331 ↑ INCREASED apoptotic process in cranial neural crest cells GO:0006915 ↑ INCREASED
Downstream
Malar hypoplasia Apoptotic depletion of cranial neural crest precursors reduces the mesenchyme available for midface (malar/zygomatic) skeletal formation.
Microcephaly P53-driven apoptosis of neural progenitors reduces brain growth, contributing to microcephaly.
Show evidence (2 references)
PMID:33601405 SUPPORT Model Organism
"RNAseq analysis of embryonic heads revealed a significant increase in exon skipping and increased levels of an alternatively spliced Mdm2 transcript lacking exon 3. Exon skipping in Mdm2 was also increased in O9-1 mouse neural crest cells after siRNA knock-down of Eftud2 and in MFDM patient..."
The neural crest-specific mouse model directly demonstrates Mdm2 mis-splicing, P53 activation, and increased cell death as the mechanism of EFTUD2-related craniofacial defects.
PMID:35893124 SUPPORT Model Organism
"Animal models of NRS and MFDM indicate that MFD results from an early depletion of neural crest progenitors through a mechanism that involves apoptosis."
A comparative review of craniofacial spliceosomopathies confirms that MFDM results from apoptosis-driven depletion of neural crest progenitors.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Mandibulofacial dysostosis with microcephaly Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

19
Cardiovascular 1
Congenital heart defect OCCASIONAL Abnormal heart morphology HP:0001627
Show evidence (1 reference)
PMID:24999515 SUPPORT Other
"Other relatively common findings (present in 25%-35% of individuals) can include cardiac anomalies, thumb anomalies, esophageal atresia/tracheoesophageal fistula, short stature, spine anomalies, and epilepsy."
GeneReviews lists cardiac anomalies among relatively common findings (25-35%).
Digestive 2
Esophageal atresia / tracheoesophageal fistula Esophageal atresia HP:0002032
Show evidence (2 references)
PMID:24470203 SUPPORT Human Clinical
"The most frequent extracranial malformation in this series is OA, followed by CHDs and skeletal abnormalities."
The 36-patient series identifies esophageal atresia (OA) as the most frequent extracranial malformation.
PMID:23188108 SUPPORT Human Clinical
"We report on 10 cases presenting with MFD, eight of whom had OA, either due to de novo 17q21.31 deletions encompassing EFTUD2 and neighbouring genes or de novo heterozygous EFTUD2 loss-of-function mutations."
Demonstrates the association of esophageal atresia with EFTUD2 loss-of-function in MFD patients.
Tracheoesophageal fistula Tracheoesophageal fistula HP:0002575
Show evidence (1 reference)
PMID:33247512 SUPPORT Human Clinical
"common features include microcephaly, cleft palate, choanal stenosis, tracheoesophageal fistula, heart problems, and seizures."
The largest single MFDM cohort lists tracheoesophageal fistula among common features.
Ear 2
Conductive hearing loss Conductive hearing impairment HP:0000405
Show evidence (1 reference)
PMID:24999515 SUPPORT Other
"malformations of the external ear, and hearing loss that is typically conductive."
GeneReviews states that hearing loss in MFDM is typically conductive.
Sensorineural hearing loss Sensorineural hearing impairment HP:0000407
Show evidence (1 reference)
PMID:22305528 SUPPORT Human Clinical
"Major sequelae, including choanal atresia, sensorineural hearing loss, and cleft palate, each occur in a significant proportion of affected individuals."
The discovery cohort reports sensorineural hearing loss as a major sequela of MFDM.
Head and Neck 5
Microcephaly Microcephaly HP:0000252
Show evidence (1 reference)
PMID:24999515 SUPPORT Other
"Mandibulofacial dysostosis with microcephaly (MFDM) is characterized by malar and mandibular hypoplasia, microcephaly (congenital or postnatal onset), intellectual disability (mild, moderate, or severe), malformations of the external ear, and hearing loss that is typically conductive."
GeneReviews lists microcephaly as a defining feature of MFDM.
Mandibular hypoplasia (micrognathia) Micrognathia HP:0000347
Show evidence (1 reference)
PMID:24999515 SUPPORT Other
"Mandibulofacial dysostosis with microcephaly (MFDM) is characterized by malar and mandibular hypoplasia"
GeneReviews identifies mandibular hypoplasia as a defining craniofacial feature.
Choanal atresia Choanal atresia HP:0000453
Show evidence (1 reference)
PMID:22305528 SUPPORT Human Clinical
"Major sequelae, including choanal atresia, sensorineural hearing loss, and cleft palate, each occur in a significant proportion of affected individuals."
Choanal atresia is documented as a major sequela in the MFDM discovery cohort.
Cleft palate Cleft palate HP:0000175
Show evidence (1 reference)
PMID:22305528 SUPPORT Human Clinical
"Major sequelae, including choanal atresia, sensorineural hearing loss, and cleft palate, each occur in a significant proportion of affected individuals."
Cleft palate is documented as a major sequela in the MFDM discovery cohort.
Facial asymmetry Facial asymmetry HP:0000324
Show evidence (1 reference)
PMID:24999515 SUPPORT Other
"Associated craniofacial malformations may include cleft palate, choanal atresia, zygomatic arch cleft (identified on cranial CT scan), and facial asymmetry."
GeneReviews lists facial asymmetry among associated craniofacial malformations.
Limbs 1
Thumb anomaly OCCASIONAL Abnormal thumb morphology HP:0001172
Show evidence (1 reference)
PMID:24999515 SUPPORT Other
"Other relatively common findings (present in 25%-35% of individuals) can include cardiac anomalies, thumb anomalies, esophageal atresia/tracheoesophageal fistula, short stature, spine anomalies, and epilepsy."
GeneReviews lists thumb anomalies among relatively common findings; the HPO parent term Abnormal thumb morphology covers the broad thumb/radial-ray anomaly spectrum (triphalangeal, hypoplastic, proximally placed, or absent thumb).
Musculoskeletal 1
Spine anomalies OCCASIONAL Abnormality of the vertebral column HP:0000925
Show evidence (1 reference)
PMID:24999515 SUPPORT Other
"Other relatively common findings (present in 25%-35% of individuals) can include cardiac anomalies, thumb anomalies, esophageal atresia/tracheoesophageal fistula, short stature, spine anomalies, and epilepsy."
GeneReviews lists spine anomalies among relatively common findings (25-35%).
Nervous System 4
Intellectual disability Intellectual disability HP:0001249
Show evidence (1 reference)
PMID:24999515 SUPPORT Other
"intellectual disability (mild, moderate, or severe)"
GeneReviews lists intellectual disability of variable severity as a core feature.
Developmental delay Global developmental delay HP:0001263
Show evidence (1 reference)
PMID:22305528 SUPPORT Human Clinical
"Mandibulofacial dysostosis with microcephaly (MFDM) is a rare sporadic syndrome comprising craniofacial malformations, microcephaly, developmental delay, and a recognizable dysmorphic appearance."
The discovery paper lists developmental delay as a core component of the MFDM syndrome.
Speech and language delay Delayed speech and language development HP:0000750
Show evidence (1 reference)
PMID:33247512 SUPPORT Human Clinical
"Family concerns focused on development, communication, and increased support."
The largest MFDM parental-survey cohort identifies communication as a leading family concern, supporting speech and language delay as a hallmark feature distinct from global developmental delay.
Seizures OCCASIONAL Seizure HP:0001250
Show evidence (1 reference)
PMID:24999515 SUPPORT Other
"Other relatively common findings (present in 25%-35% of individuals) can include cardiac anomalies, thumb anomalies, esophageal atresia/tracheoesophageal fistula, short stature, spine anomalies, and epilepsy."
GeneReviews lists epilepsy among relatively common findings (25-35%).
Growth 1
Short stature OCCASIONAL Short stature HP:0004322
Show evidence (1 reference)
PMID:24999515 SUPPORT Other
"Other relatively common findings (present in 25%-35% of individuals) can include cardiac anomalies, thumb anomalies, esophageal atresia/tracheoesophageal fistula, short stature, spine anomalies, and epilepsy."
GeneReviews lists short stature among relatively common findings (25-35%).
Other 2
Malar hypoplasia Hypoplasia of the zygomatic bone HP:0010669
Show evidence (1 reference)
PMID:24999515 SUPPORT Other
"Mandibulofacial dysostosis with microcephaly (MFDM) is characterized by malar and mandibular hypoplasia"
GeneReviews identifies malar hypoplasia as a defining craniofacial feature.
External ear malformation (microtia) Microtia HP:0008551
Show evidence (1 reference)
PMID:24470203 SUPPORT Human Clinical
"MFD, external ear anomalies, and intellectual deficiency occur at a higher frequency than microcephaly."
The 36-patient series documents external ear anomalies as among the most frequent features of EFTUD2 haploinsufficiency.
🧬

Genetic Associations

1
EFTUD2 (Pathogenic Variants)
Gene: EFTUD2 hgnc:30858
Show evidence (1 reference)
PMID:22305528 SUPPORT Human Clinical
"To define the etiology of MFDM, we employed whole-exome sequencing of four unrelated affected individuals and identified heterozygous mutations or deletions of EFTUD2 in all four. Validation studies of eight additional individuals with MFDM demonstrated causative EFTUD2 mutations in all affected..."
Whole-exome sequencing and validation establish EFTUD2 heterozygous loss-of-function as the cause of MFDM.
💊

Medical Actions

5
Multidisciplinary craniofacial surgical management
Action: surgical procedure MAXO:0000004
Individualized treatment of craniofacial manifestations by a multidisciplinary team, which may include oromaxillofacial surgery, plastic surgery, otolaryngology, and dentistry/orthodontics. Esophageal atresia/tracheoesophageal fistula, cardiac defects, renal anomalies, and thumb anomalies are treated in a routine surgical/medical manner.
Show evidence (1 reference)
PMID:24999515 SUPPORT Other
"Individualized treatment of craniofacial manifestations is managed by a multidisciplinary team which may include: oromaxillofacial surgery, plastic surgery, otolaryngology, dentistry/orthodontics, and occupational and speech-language therapy."
GeneReviews describes multidisciplinary surgical management of craniofacial manifestations.
Neonatal airway management (intubation/tracheostomy)
Action: tracheostomy MAXO:0000504
Newborn infants may have airway compromise at delivery due to choanal atresia and/or mandibular hypoplasia, requiring intubation and/or tracheostomy for initial stabilization.
Show evidence (1 reference)
PMID:24999515 SUPPORT Other
"Newborn infants may have airway compromise at delivery due to choanal atresia and/or mandibular hypoplasia, requiring intubation and/or tracheostomy for initial stabilization."
GeneReviews documents neonatal airway stabilization including tracheostomy.
Hearing loss management (hearing aids / cochlear implants)
Action: hearing aid usage MAXO:0009030
Treatment of hearing loss is individualized and may involve conventional hearing aid(s), bone-anchored hearing aid(s), and/or cochlear implant(s).
Show evidence (1 reference)
PMID:24999515 SUPPORT Other
"Treatment of hearing loss is individualized, and may involve conventional hearing aid(s), bone-anchored hearing aid(s), and/or cochlear implant(s)."
GeneReviews describes hearing aids and cochlear implants for management of hearing loss.
Developmental and speech-language therapy
Action: speech therapy MAXO:0000930
Early individualized educational and therapy plans, including occupational and speech-language therapy, are devised as needed to optimize developmental outcome.
Show evidence (1 reference)
PMID:24999515 SUPPORT Other
"Early individualized educational and therapy plans are devised as needed to optimize developmental outcome."
GeneReviews describes early educational and therapy plans, including speech-language therapy.
Genetic counseling
Action: Genetic Counseling NCIT:C15240
Genetic counseling addresses the autosomal dominant, predominantly de novo inheritance; once the causative EFTUD2 variant is identified, prenatal and preimplantation genetic testing are possible.
Show evidence (1 reference)
PMID:24999515 SUPPORT Other
"Once the causative EFTUD2 pathogenic variant has been identified in an affected family member, prenatal testing and preimplantation genetic testing are possible."
GeneReviews supports genetic counseling and reproductive testing options for MFDM families.
{ }

Source YAML

click to show 
name: Mandibulofacial dysostosis with microcephaly
creation_date: "2026-06-04T00:00:00Z"
category: Mendelian
description: >-
  Mandibulofacial dysostosis with microcephaly (MFDM; Guion-Almeida type) is a
  rare autosomal dominant multiple congenital anomaly syndrome caused by de novo
  haploinsufficiency of EFTUD2, the gene encoding U5-116kD/SNU114, a core GTPase
  of the U5 small nuclear ribonucleoprotein (snRNP) of the major spliceosome. It
  is characterized by malar and mandibular hypoplasia, microcephaly (congenital
  or postnatal), external ear malformations (microtia) with conductive and/or
  sensorineural hearing loss, cleft palate, choanal atresia, esophageal
  atresia/tracheoesophageal fistula, congenital heart defects, thumb/radial-ray
  anomalies, and developmental delay with intellectual disability. MFDM was the
  first multiple-malformation syndrome attributed to a defect of the major
  spliceosome.
disease_term:
  preferred_term: Mandibulofacial dysostosis with microcephaly
  term:
    id: MONDO:0012516
    label: mandibulofacial dysostosis-microcephaly syndrome
parents:
- hereditary disease
references:
- reference: PMID:24999515
  title: "Mandibulofacial Dysostosis with Microcephaly."
  tags:
  - GeneReviews
inheritance:
- name: Autosomal dominant inheritance
  description: >-
    MFDM is an autosomal dominant disorder. Most affected individuals have a de
    novo heterozygous loss-of-function variant in EFTUD2; in a minority the
    variant is inherited from a mildly affected parent.
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:24999515
    reference_title: "Mandibulofacial Dysostosis with Microcephaly."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      MFDM is an autosomal dominant disorder. Most individuals diagnosed with
      MFDM to date are presumed to have the disorder as the result of a de novo
      EFTUD2 pathogenic variant; in some individuals, the causative pathogenic
      variant was inherited from a parent with a milder phenotypic presentation.
    explanation: GeneReviews directly states the autosomal dominant, predominantly de novo inheritance of MFDM.
  - reference: PMID:33247512
    reference_title: "Mandibulofacial dysostosis with microcephaly: An expansion of the phenotype via parental survey."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Targeted Sanger sequencing for families of seven individuals demonstrated
      de novo variants, for a total of 91.9% de novo EFTUD2 variants (n = 34/37).
    explanation: A large patient cohort confirms that the great majority of EFTUD2 variants causing MFDM arise de novo.
pathophysiology:
- name: EFTUD2 haploinsufficiency impairs U5 snRNP spliceosome function
  description: >-
    MFDM is caused by heterozygous loss-of-function variants (null alleles,
    frameshifts, intragenic and contiguous 17q21.31 deletions, and a subset of
    missense and splice-altering variants) in EFTUD2. EFTUD2 encodes U5-116kD
    (SNU114), a highly conserved spliceosomal GTPase that is a core component of
    the U5 snRNP with a central regulatory role in catalytic pre-mRNA splicing
    and post-splicing spliceosome disassembly. Reduced EFTUD2 dosage impairs the
    major spliceosome, making MFDM the first multiple-malformation syndrome
    attributed to a defect of the major spliceosome.
  genes:
  - preferred_term: EFTUD2
    modifier: DECREASED
    term:
      id: hgnc:30858
      label: EFTUD2
  biological_processes:
  - preferred_term: mRNA splicing via the major spliceosome
    modifier: ABNORMAL
    term:
      id: GO:0000398
      label: mRNA splicing, via spliceosome
  cellular_components:
  - preferred_term: U5 snRNP
    modifier: DECREASED
    term:
      id: GO:0005682
      label: U5 snRNP
  evidence:
  - reference: PMID:22305528
    reference_title: "Haploinsufficiency of a spliceosomal GTPase encoded by EFTUD2 causes mandibulofacial dysostosis with microcephaly."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A range of EFTUD2-mutation types, including null alleles and frameshifts,
      is seen in MFDM, consistent with haploinsufficiency; segregation is de
      novo in all cases assessed to date. U5-116kD, the protein encoded by
      EFTUD2, is a highly conserved spliceosomal GTPase with a central
      regulatory role in catalytic splicing and post-splicing-complex
      disassembly.
    explanation: The original gene-discovery paper establishes EFTUD2 haploinsufficiency and the role of U5-116kD as a core spliceosomal GTPase.
  - reference: PMID:22305528
    reference_title: "Haploinsufficiency of a spliceosomal GTPase encoded by EFTUD2 causes mandibulofacial dysostosis with microcephaly."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      MFDM is the first multiple-malformation syndrome attributed to a defect of
      the major spliceosome.
    explanation: Supports the classification of MFDM as a major-spliceosome disorder.
  - reference: PMID:32333448
    reference_title: "EFTUD2 missense variants disrupt protein function and splicing in mandibulofacial dysostosis Guion-Almeida type."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Pathogenic variants in the core spliceosome U5 small nuclear
      ribonucleoprotein gene EFTUD2/SNU114 cause the craniofacial disorder
      mandibulofacial dysostosis Guion-Almeida type (MFDGA).
    explanation: Functional yeast and minigene assays confirm EFTUD2 as a core U5 snRNP gene whose variants cause MFDGA by loss-of-function.
  downstream:
  - target: Disrupted pre-mRNA splicing in neural crest and craniofacial development
    description: >-
      Impaired U5 snRNP/spliceosome function reduces fidelity and efficiency of
      pre-mRNA splicing during embryogenesis, including in cranial neural crest
      derivatives.
    evidence:
    - reference: PMID:23188108
      reference_title: "EFTUD2 haploinsufficiency leads to syndromic oesophageal atresia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        emphasise the necessity of mRNA maturation through the spliceosome complex
        for global growth and within specific regions of the embryo during
        development.
      explanation: Links the spliceosomal defect to a developmental requirement for spliceosome-dependent mRNA maturation.
  - target: Mdm2 mis-splicing activates p53-dependent neural crest apoptosis
    description: >-
      Impaired spliceosome function increases exon skipping, including
      mis-splicing of Mdm2, coupling the core splicing defect to P53-pathway
      activation.
    evidence:
    - reference: PMID:33601405
      reference_title: "Mutation in Eftud2 causes craniofacial defects in mice via mis-splicing of Mdm2 and increased P53."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        RNAseq analysis of embryonic heads revealed a significant increase in
        exon skipping and increased levels of an alternatively spliced Mdm2
        transcript lacking exon 3.
      explanation: Connects EFTUD2-mediated splicing impairment to Mdm2 mis-splicing.
- name: Disrupted pre-mRNA splicing in neural crest and craniofacial development
  description: >-
    The major spliceosome is broadly required for pre-mRNA maturation during
    embryogenesis, including in cranial neural crest cells that give rise to
    craniofacial skeletal and connective tissues. Insufficient EFTUD2 dosage
    disrupts splicing-dependent gene expression during neural crest and
    craniofacial morphogenesis, contributing to malar/mandibular hypoplasia,
    ear and palatal malformations, and brain underdevelopment. A zebrafish
    eftud2-null model shows reduced head size, small eye, and widespread
    apoptosis in the developing brain, eye, and spinal cord, demonstrating a
    conserved requirement during development of diverse tissues.
  cell_types:
  - preferred_term: migratory neural crest cell
    term:
      id: CL:0000333
      label: migratory neural crest cell
  biological_processes:
  - preferred_term: mRNA splicing via the major spliceosome
    modifier: ABNORMAL
    term:
      id: GO:0000398
      label: mRNA splicing, via spliceosome
  evidence:
  - reference: PMID:23188108
    reference_title: "EFTUD2 haploinsufficiency leads to syndromic oesophageal atresia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      emphasise the necessity of mRNA maturation through the spliceosome complex
      for global growth and within specific regions of the embryo during
      development.
    explanation: Supports the requirement of spliceosome-dependent mRNA maturation for normal embryonic growth and regional development.
  - reference: PMID:26118977
    reference_title: "EFTUD2 deficiency in vertebrates: Identification of a novel human mutation and generation of a zebrafish model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Homozygous mutants displayed a reduced head size, small eye, curved body,
      and early embryonic lethality. Apoptosis assays demonstrated a striking
      increase in terminal deoxynucleotidyl transferase-mediated deoxyuridine
      triphosphate nick end-labeling (TUNEL)-positive cells in the developing
      brain, eye, spinal cord, and other tissues starting at 30 hours
      postfertilization.
    explanation: The zebrafish eftud2 model recapitulates reduced head size and shows developmental apoptosis, supporting a conserved role of EFTUD2 in craniofacial and neural development.
  downstream:
  - target: Malar hypoplasia
    description: >-
      Disrupted splicing-dependent gene expression in cranial neural crest
      derivatives impairs midface (malar/zygomatic) skeletal development.
    evidence:
    - reference: PMID:22305528
      reference_title: "Haploinsufficiency of a spliceosomal GTPase encoded by EFTUD2 causes mandibulofacial dysostosis with microcephaly."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Mandibulofacial dysostosis with microcephaly (MFDM) is a rare sporadic
        syndrome comprising craniofacial malformations, microcephaly,
        developmental delay, and a recognizable dysmorphic appearance.
      explanation: Connects the spliceosomal/neural-crest mechanism to the craniofacial malformations of MFDM.
  - target: Mandibular hypoplasia (micrognathia)
    description: >-
      Disrupted neural crest-derived first pharyngeal arch development impairs
      mandibular growth.
    evidence:
    - reference: PMID:22305528
      reference_title: "Haploinsufficiency of a spliceosomal GTPase encoded by EFTUD2 causes mandibulofacial dysostosis with microcephaly."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Mandibulofacial dysostosis with microcephaly (MFDM) is a rare sporadic
        syndrome comprising craniofacial malformations, microcephaly,
        developmental delay, and a recognizable dysmorphic appearance.
      explanation: Connects the spliceosomal/neural-crest mechanism to mandibulofacial dysostosis.
  - target: Microcephaly
    description: >-
      Disrupted splicing-dependent gene expression and increased apoptosis in
      the developing brain contribute to reduced brain growth and microcephaly.
    evidence:
    - reference: PMID:26118977
      reference_title: "EFTUD2 deficiency in vertebrates: Identification of a novel human mutation and generation of a zebrafish model."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Homozygous mutants displayed a reduced head size, small eye, curved body,
        and early embryonic lethality.
      explanation: The zebrafish model links eftud2 deficiency to reduced head size, modeling the microcephaly seen in MFDM.
  - target: External ear malformation (microtia)
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Conductive hearing loss
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Sensorineural hearing loss
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Choanal atresia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Cleft palate
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Esophageal atresia / tracheoesophageal fistula
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Tracheoesophageal fistula
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Congenital heart defect
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Thumb anomaly
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Intellectual disability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Developmental delay
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Speech and language delay
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Seizures
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Short stature
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Spine anomalies
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Facial asymmetry
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Mdm2 mis-splicing activates p53-dependent neural crest apoptosis
  description: >-
    In vertebrate models of EFTUD2 deficiency, the splicing defect causes
    increased exon skipping, including an alternatively spliced Mdm2 transcript
    lacking exon 3. Reduced functional MDM2 stabilizes and activates nuclear
    P53, increasing expression of P53-target genes and triggering apoptosis of
    cranial neural crest cells and neural progenitors. Early depletion of these
    craniofacial precursor populations drives the craniofacial malformations and
    microcephaly of MFDM. The mechanism is partly p53-dependent: pharmacologic
    P53 inhibition (pifithrin-alpha) partially rescues craniofacial development,
    while Trp53 deletion reduces apoptosis without fully rescuing morphology,
    implying additional p53-independent mis-splicing contributions.
  cell_types:
  - preferred_term: migratory neural crest cell
    term:
      id: CL:0000333
      label: migratory neural crest cell
  biological_processes:
  - preferred_term: signal transduction by p53 class mediator
    modifier: INCREASED
    term:
      id: GO:0072331
      label: signal transduction by p53 class mediator
  - preferred_term: apoptotic process in cranial neural crest cells
    modifier: INCREASED
    term:
      id: GO:0006915
      label: apoptotic process
  evidence:
  - reference: PMID:33601405
    reference_title: "Mutation in Eftud2 causes craniofacial defects in mice via mis-splicing of Mdm2 and increased P53."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      RNAseq analysis of embryonic heads revealed a significant increase in exon
      skipping and increased levels of an alternatively spliced Mdm2 transcript
      lacking exon 3. Exon skipping in Mdm2 was also increased in O9-1 mouse
      neural crest cells after siRNA knock-down of Eftud2 and in MFDM patient
      cells. Moreover, we found increased nuclear P53, higher expression of
      P53-target genes and increased cell death.
    explanation: The neural crest-specific mouse model directly demonstrates Mdm2 mis-splicing, P53 activation, and increased cell death as the mechanism of EFTUD2-related craniofacial defects.
  - reference: PMID:35893124
    reference_title: "The Core Splicing Factors EFTUD2, SNRPB and TXNL4A Are Essential for Neural Crest and Craniofacial Development."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Animal models of NRS and MFDM indicate that MFD results from an early
      depletion of neural crest progenitors through a mechanism that involves
      apoptosis.
    explanation: A comparative review of craniofacial spliceosomopathies confirms that MFDM results from apoptosis-driven depletion of neural crest progenitors.
  downstream:
  - target: Malar hypoplasia
    description: >-
      Apoptotic depletion of cranial neural crest precursors reduces the
      mesenchyme available for midface (malar/zygomatic) skeletal formation.
    evidence:
    - reference: PMID:33601405
      reference_title: "Mutation in Eftud2 causes craniofacial defects in mice via mis-splicing of Mdm2 and increased P53."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Homozygous deletion of Eftud2 causes brain and craniofacial
        malformations, affecting the same precursors as in MFDM patients.
      explanation: Neural-crest-specific Eftud2 loss produces craniofacial malformations affecting the same precursors as MFDM patients.
  - target: Microcephaly
    description: >-
      P53-driven apoptosis of neural progenitors reduces brain growth,
      contributing to microcephaly.
    evidence:
    - reference: PMID:33601405
      reference_title: "Mutation in Eftud2 causes craniofacial defects in mice via mis-splicing of Mdm2 and increased P53."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Homozygous deletion of Eftud2 causes brain and craniofacial
        malformations, affecting the same precursors as in MFDM patients.
      explanation: The same model links Eftud2 loss to brain malformations, supporting the microcephaly phenotype.
phenotypes:
- name: Microcephaly
  description: >-
    Microcephaly, of congenital or postnatal onset, is a core feature of MFDM.
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: PMID:24999515
    reference_title: "Mandibulofacial Dysostosis with Microcephaly."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Mandibulofacial dysostosis with microcephaly (MFDM) is characterized by
      malar and mandibular hypoplasia, microcephaly (congenital or postnatal
      onset), intellectual disability (mild, moderate, or severe),
      malformations of the external ear, and hearing loss that is typically
      conductive.
    explanation: GeneReviews lists microcephaly as a defining feature of MFDM.
- name: Malar hypoplasia
  description: >-
    Hypoplasia of the malar (zygomatic) region is a hallmark craniofacial
    feature, part of the mandibulofacial dysostosis.
  phenotype_term:
    preferred_term: Malar hypoplasia
    term:
      id: HP:0010669
      label: Hypoplasia of the zygomatic bone
  evidence:
  - reference: PMID:24999515
    reference_title: "Mandibulofacial Dysostosis with Microcephaly."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Mandibulofacial dysostosis with microcephaly (MFDM) is characterized by
      malar and mandibular hypoplasia
    explanation: GeneReviews identifies malar hypoplasia as a defining craniofacial feature.
- name: Mandibular hypoplasia (micrognathia)
  description: >-
    Mandibular hypoplasia (small/retruded mandible) is a defining feature of the
    mandibulofacial dysostosis component and may contribute to neonatal airway
    compromise.
  phenotype_term:
    preferred_term: Mandibular hypoplasia
    term:
      id: HP:0000347
      label: Micrognathia
  evidence:
  - reference: PMID:24999515
    reference_title: "Mandibulofacial Dysostosis with Microcephaly."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Mandibulofacial dysostosis with microcephaly (MFDM) is characterized by
      malar and mandibular hypoplasia
    explanation: GeneReviews identifies mandibular hypoplasia as a defining craniofacial feature.
- name: External ear malformation (microtia)
  description: >-
    Malformations of the external ear, ranging from dysplasia to microtia, are
    very common and occur at higher frequency than microcephaly.
  phenotype_term:
    preferred_term: Microtia / external ear malformation
    term:
      id: HP:0008551
      label: Microtia
  evidence:
  - reference: PMID:24470203
    reference_title: "Delineation of EFTUD2 haploinsufficiency-related phenotypes through a series of 36 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      MFD, external ear anomalies, and intellectual deficiency occur at a higher
      frequency than microcephaly.
    explanation: The 36-patient series documents external ear anomalies as among the most frequent features of EFTUD2 haploinsufficiency.
- name: Conductive hearing loss
  description: >-
    Hearing loss in MFDM is typically conductive, often related to external and
    middle ear malformations.
  phenotype_term:
    preferred_term: Conductive hearing impairment
    term:
      id: HP:0000405
      label: Conductive hearing impairment
  evidence:
  - reference: PMID:24999515
    reference_title: "Mandibulofacial Dysostosis with Microcephaly."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      malformations of the external ear, and hearing loss that is typically
      conductive.
    explanation: GeneReviews states that hearing loss in MFDM is typically conductive.
- name: Sensorineural hearing loss
  description: >-
    Sensorineural hearing loss occurs in a significant proportion of affected
    individuals.
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:22305528
    reference_title: "Haploinsufficiency of a spliceosomal GTPase encoded by EFTUD2 causes mandibulofacial dysostosis with microcephaly."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Major sequelae, including choanal atresia, sensorineural hearing loss, and
      cleft palate, each occur in a significant proportion of affected
      individuals.
    explanation: The discovery cohort reports sensorineural hearing loss as a major sequela of MFDM.
- name: Choanal atresia
  description: >-
    Choanal atresia is a major craniofacial sequela and a cause of neonatal
    airway compromise.
  phenotype_term:
    preferred_term: Choanal atresia
    term:
      id: HP:0000453
      label: Choanal atresia
  evidence:
  - reference: PMID:22305528
    reference_title: "Haploinsufficiency of a spliceosomal GTPase encoded by EFTUD2 causes mandibulofacial dysostosis with microcephaly."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Major sequelae, including choanal atresia, sensorineural hearing loss, and
      cleft palate, each occur in a significant proportion of affected
      individuals.
    explanation: Choanal atresia is documented as a major sequela in the MFDM discovery cohort.
- name: Cleft palate
  description: >-
    Cleft palate is among the major craniofacial malformations associated with
    MFDM.
  phenotype_term:
    preferred_term: Cleft palate
    term:
      id: HP:0000175
      label: Cleft palate
  evidence:
  - reference: PMID:22305528
    reference_title: "Haploinsufficiency of a spliceosomal GTPase encoded by EFTUD2 causes mandibulofacial dysostosis with microcephaly."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Major sequelae, including choanal atresia, sensorineural hearing loss, and
      cleft palate, each occur in a significant proportion of affected
      individuals.
    explanation: Cleft palate is documented as a major sequela in the MFDM discovery cohort.
- name: Esophageal atresia / tracheoesophageal fistula
  description: >-
    Esophageal atresia, frequently with tracheoesophageal fistula, is the most
    frequent extracranial malformation and defines a syndromic OA entity within
    EFTUD2 haploinsufficiency.
  phenotype_term:
    preferred_term: Esophageal atresia
    term:
      id: HP:0002032
      label: Esophageal atresia
  evidence:
  - reference: PMID:24470203
    reference_title: "Delineation of EFTUD2 haploinsufficiency-related phenotypes through a series of 36 patients."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most frequent extracranial malformation in this series is OA, followed
      by CHDs and skeletal abnormalities.
    explanation: The 36-patient series identifies esophageal atresia (OA) as the most frequent extracranial malformation.
  - reference: PMID:23188108
    reference_title: "EFTUD2 haploinsufficiency leads to syndromic oesophageal atresia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report on 10 cases presenting with MFD, eight of whom had OA, either
      due to de novo 17q21.31 deletions encompassing EFTUD2 and neighbouring
      genes or de novo heterozygous EFTUD2 loss-of-function mutations.
    explanation: Demonstrates the association of esophageal atresia with EFTUD2 loss-of-function in MFD patients.
- name: Tracheoesophageal fistula
  description: >-
    Tracheoesophageal fistula commonly accompanies esophageal atresia in MFDM.
  phenotype_term:
    preferred_term: Tracheoesophageal fistula
    term:
      id: HP:0002575
      label: Tracheoesophageal fistula
  evidence:
  - reference: PMID:33247512
    reference_title: "Mandibulofacial dysostosis with microcephaly: An expansion of the phenotype via parental survey."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      common features include microcephaly, cleft palate, choanal stenosis,
      tracheoesophageal fistula, heart problems, and seizures.
    explanation: The largest single MFDM cohort lists tracheoesophageal fistula among common features.
- name: Congenital heart defect
  description: >-
    Congenital heart defects are a relatively common associated finding in MFDM.
  phenotype_term:
    preferred_term: Congenital heart defect
    term:
      id: HP:0001627
      label: Abnormal heart morphology
  evidence:
  - reference: PMID:24999515
    reference_title: "Mandibulofacial Dysostosis with Microcephaly."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Other relatively common findings (present in 25%-35% of individuals) can
      include cardiac anomalies, thumb anomalies, esophageal
      atresia/tracheoesophageal fistula, short stature, spine anomalies, and
      epilepsy.
    explanation: GeneReviews lists cardiac anomalies among relatively common findings (25-35%).
  frequency: OCCASIONAL
- name: Thumb anomaly
  description: >-
    Thumb and radial-ray anomalies occur in a relatively common minority of
    individuals.
  phenotype_term:
    preferred_term: Thumb anomaly
    term:
      id: HP:0001172
      label: Abnormal thumb morphology
  evidence:
  - reference: PMID:24999515
    reference_title: "Mandibulofacial Dysostosis with Microcephaly."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Other relatively common findings (present in 25%-35% of individuals) can
      include cardiac anomalies, thumb anomalies, esophageal
      atresia/tracheoesophageal fistula, short stature, spine anomalies, and
      epilepsy.
    explanation: GeneReviews lists thumb anomalies among relatively common findings; the HPO parent term Abnormal thumb morphology covers the broad thumb/radial-ray anomaly spectrum (triphalangeal, hypoplastic, proximally placed, or absent thumb).
  frequency: OCCASIONAL
- name: Intellectual disability
  description: >-
    Intellectual disability, ranging from mild to severe, is a core feature and
    occurs at higher frequency than microcephaly.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:24999515
    reference_title: "Mandibulofacial Dysostosis with Microcephaly."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      intellectual disability (mild, moderate, or severe)
    explanation: GeneReviews lists intellectual disability of variable severity as a core feature.
- name: Developmental delay
  description: >-
    Developmental delay is a consistent feature of MFDM and a primary family
    concern.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:22305528
    reference_title: "Haploinsufficiency of a spliceosomal GTPase encoded by EFTUD2 causes mandibulofacial dysostosis with microcephaly."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mandibulofacial dysostosis with microcephaly (MFDM) is a rare sporadic
      syndrome comprising craniofacial malformations, microcephaly,
      developmental delay, and a recognizable dysmorphic appearance.
    explanation: The discovery paper lists developmental delay as a core component of the MFDM syndrome.
- name: Speech and language delay
  description: >-
    Delayed speech and language development is disproportionately affected in
    MFDM relative to overall development, and communication is a leading family
    concern.
  phenotype_term:
    preferred_term: Speech and language delay
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:33247512
    reference_title: "Mandibulofacial dysostosis with microcephaly: An expansion of the phenotype via parental survey."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Family concerns focused on development, communication, and increased
      support.
    explanation: The largest MFDM parental-survey cohort identifies communication as a leading family concern, supporting speech and language delay as a hallmark feature distinct from global developmental delay.
- name: Seizures
  description: >-
    Epilepsy/seizures occur in a relatively common minority of affected
    individuals.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:24999515
    reference_title: "Mandibulofacial Dysostosis with Microcephaly."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Other relatively common findings (present in 25%-35% of individuals) can
      include cardiac anomalies, thumb anomalies, esophageal
      atresia/tracheoesophageal fistula, short stature, spine anomalies, and
      epilepsy.
    explanation: GeneReviews lists epilepsy among relatively common findings (25-35%).
  frequency: OCCASIONAL
- name: Short stature
  description: >-
    Short stature is a relatively common associated finding, managed
    expectantly.
  phenotype_term:
    preferred_term: Short stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:24999515
    reference_title: "Mandibulofacial Dysostosis with Microcephaly."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Other relatively common findings (present in 25%-35% of individuals) can
      include cardiac anomalies, thumb anomalies, esophageal
      atresia/tracheoesophageal fistula, short stature, spine anomalies, and
      epilepsy.
    explanation: GeneReviews lists short stature among relatively common findings (25-35%).
  frequency: OCCASIONAL
- name: Spine anomalies
  description: >-
    Vertebral/spine anomalies occur in a relatively common minority of affected
    individuals.
  phenotype_term:
    preferred_term: Spine anomalies
    term:
      id: HP:0000925
      label: Abnormality of the vertebral column
  evidence:
  - reference: PMID:24999515
    reference_title: "Mandibulofacial Dysostosis with Microcephaly."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Other relatively common findings (present in 25%-35% of individuals) can
      include cardiac anomalies, thumb anomalies, esophageal
      atresia/tracheoesophageal fistula, short stature, spine anomalies, and
      epilepsy.
    explanation: GeneReviews lists spine anomalies among relatively common findings (25-35%).
  frequency: OCCASIONAL
- name: Facial asymmetry
  description: >-
    Facial asymmetry is among the associated craniofacial malformations.
  phenotype_term:
    preferred_term: Facial asymmetry
    term:
      id: HP:0000324
      label: Facial asymmetry
  evidence:
  - reference: PMID:24999515
    reference_title: "Mandibulofacial Dysostosis with Microcephaly."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Associated craniofacial malformations may include cleft palate, choanal
      atresia, zygomatic arch cleft (identified on cranial CT scan), and facial
      asymmetry.
    explanation: GeneReviews lists facial asymmetry among associated craniofacial malformations.
genetic:
- name: EFTUD2
  gene_term:
    preferred_term: EFTUD2
    term:
      id: hgnc:30858
      label: EFTUD2
  association: Pathogenic Variants
  evidence:
  - reference: PMID:22305528
    reference_title: "Haploinsufficiency of a spliceosomal GTPase encoded by EFTUD2 causes mandibulofacial dysostosis with microcephaly."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      To define the etiology of MFDM, we employed whole-exome sequencing of four
      unrelated affected individuals and identified heterozygous mutations or
      deletions of EFTUD2 in all four. Validation studies of eight additional
      individuals with MFDM demonstrated causative EFTUD2 mutations in all
      affected individuals tested.
    explanation: Whole-exome sequencing and validation establish EFTUD2 heterozygous loss-of-function as the cause of MFDM.
treatments:
- name: Multidisciplinary craniofacial surgical management
  description: >-
    Individualized treatment of craniofacial manifestations by a
    multidisciplinary team, which may include oromaxillofacial surgery, plastic
    surgery, otolaryngology, and dentistry/orthodontics. Esophageal
    atresia/tracheoesophageal fistula, cardiac defects, renal anomalies, and
    thumb anomalies are treated in a routine surgical/medical manner.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:24999515
    reference_title: "Mandibulofacial Dysostosis with Microcephaly."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Individualized treatment of craniofacial manifestations is managed by a
      multidisciplinary team which may include: oromaxillofacial surgery,
      plastic surgery, otolaryngology, dentistry/orthodontics, and occupational
      and speech-language therapy.
    explanation: GeneReviews describes multidisciplinary surgical management of craniofacial manifestations.
- name: Neonatal airway management (intubation/tracheostomy)
  description: >-
    Newborn infants may have airway compromise at delivery due to choanal
    atresia and/or mandibular hypoplasia, requiring intubation and/or
    tracheostomy for initial stabilization.
  treatment_term:
    preferred_term: tracheostomy
    term:
      id: MAXO:0000504
      label: tracheostomy
  evidence:
  - reference: PMID:24999515
    reference_title: "Mandibulofacial Dysostosis with Microcephaly."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Newborn infants may have airway compromise at delivery due to choanal
      atresia and/or mandibular hypoplasia, requiring intubation and/or
      tracheostomy for initial stabilization.
    explanation: GeneReviews documents neonatal airway stabilization including tracheostomy.
- name: Hearing loss management (hearing aids / cochlear implants)
  description: >-
    Treatment of hearing loss is individualized and may involve conventional
    hearing aid(s), bone-anchored hearing aid(s), and/or cochlear implant(s).
  treatment_term:
    preferred_term: hearing aid usage
    term:
      id: MAXO:0009030
      label: hearing aid usage
  evidence:
  - reference: PMID:24999515
    reference_title: "Mandibulofacial Dysostosis with Microcephaly."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Treatment of hearing loss is individualized, and may involve conventional
      hearing aid(s), bone-anchored hearing aid(s), and/or cochlear implant(s).
    explanation: GeneReviews describes hearing aids and cochlear implants for management of hearing loss.
- name: Developmental and speech-language therapy
  description: >-
    Early individualized educational and therapy plans, including occupational
    and speech-language therapy, are devised as needed to optimize developmental
    outcome.
  treatment_term:
    preferred_term: speech therapy
    term:
      id: MAXO:0000930
      label: speech therapy
  evidence:
  - reference: PMID:24999515
    reference_title: "Mandibulofacial Dysostosis with Microcephaly."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Early individualized educational and therapy plans are devised as needed
      to optimize developmental outcome.
    explanation: GeneReviews describes early educational and therapy plans, including speech-language therapy.
- name: Genetic counseling
  description: >-
    Genetic counseling addresses the autosomal dominant, predominantly de novo
    inheritance; once the causative EFTUD2 variant is identified, prenatal and
    preimplantation genetic testing are possible.
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:24999515
    reference_title: "Mandibulofacial Dysostosis with Microcephaly."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Once the causative EFTUD2 pathogenic variant has been identified in an
      affected family member, prenatal testing and preimplantation genetic
      testing are possible.
    explanation: GeneReviews supports genetic counseling and reproductive testing options for MFDM families.
📚

References & Deep Research

References

1
PMID:24999515
Mandibulofacial Dysostosis with Microcephaly.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 27 citations 2026-06-04T00:23:43.157833

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Mandibulofacial dysostosis with microcephaly
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Mandibulofacial dysostosis with microcephaly covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Disease Characteristics Report: Mandibulofacial dysostosis with microcephaly (MFDM)

Executive summary

Mandibulofacial dysostosis with microcephaly (MFDM) is a rare, predominantly de novo autosomal dominant craniofacial malformation syndrome caused by heterozygous loss-of-function variants or deletions in EFTUD2, which encodes the U5-116kD spliceosomal GTPase (a U5 snRNP core factor). Clinically, MFDM features mandibular/malar hypoplasia, external ear malformations with hearing loss, choanal and/or aural atresia, cleft palate, microcephaly, and developmental delay with prominent expressive language impairment; extracranial anomalies (cardiac defects, esophageal atresia/TEF, limb anomalies, seizures) occur in a substantial minority. Mechanistically, vertebrate models support a causal chain from EFTUD2-mediated splicing defects to p53-pathway activation and apoptosis in cranial neural crest and neural progenitor populations, driving craniofacial and neurodevelopmental phenotypes; p53 inhibition partially rescues craniofacial development in a mouse model but genetic Trp53 deletion does not fully rescue, implying additional p53-independent mechanisms. (lines2012haploinsufficiencyofa pages 1-2, lines2012haploinsufficiencyofa pages 4-5, beauchamp2022craniofacialdefectsin pages 1-2, beauchamp2021mutationineftud2 pages 10-12, chen2024atypicalmandibulofacialdysostosis pages 1-2)

Target disease

  • Disease name: Mandibulofacial dysostosis with microcephaly (MFDM) (lines2012haploinsufficiencyofa pages 1-2, luquetti2013“mandibulofacialdysostosiswith pages 1-3)
  • Category: Mendelian
  • MONDO ID: MONDO_0012516 (“mandibulofacial dysostosis-microcephaly syndrome”) (OpenTargets Search: mandibulofacial dysostosis with microcephaly)

1. Disease information

1.1 Definition / overview

MFDM is a rare craniofacial-malformation syndrome characterized by mandibulofacial dysostosis and microcephaly with developmental delay and a recognizable facial gestalt; major recurrent findings include choanal atresia, cleft palate, and hearing loss. (lines2012haploinsufficiencyofa pages 1-2, lines2012haploinsufficiencyofa pages 4-5)

1.2 Key identifiers

  • OMIM phenotype: 610536 (MFDM) (chen2024atypicalmandibulofacialdysostosis pages 5-6, luquetti2013“mandibulofacialdysostosiswith pages 1-3)
  • MONDO: MONDO_0012516 (OpenTargets Search: mandibulofacial dysostosis with microcephaly)

Not retrieved with available tools in this run: Orphanet ID, MeSH descriptor, ICD-10/ICD-11 codes.

1.3 Synonyms and alternative names

  • “Mandibulofacial dysostosis with microcephaly (MFDM)” (lines2012haploinsufficiencyofa pages 1-2, luquetti2013“mandibulofacialdysostosiswith pages 1-3)
  • “Mandibulofacial dysostosis, Guion-Almeida type” / “Guion-Almeida syndrome” (used in mechanistic and review contexts) (beauchamp2020missplicingofmdm2 pages 19-23, park2022thecoresplicing pages 13-14)
  • “Mandibulofacial dysostosis-microcephaly syndrome” (MONDO naming) (OpenTargets Search: mandibulofacial dysostosis with microcephaly)

1.4 Evidence source type

Evidence used here is derived from aggregated disease-level resources (OpenTargets disease–gene association) and primary patient cohorts/case reports/case series plus experimental model-organism studies. (OpenTargets Search: mandibulofacial dysostosis with microcephaly, lines2012haploinsufficiencyofa pages 1-2, kohailan2022adenovo pages 2-4, beauchamp2021mutationineftud2 pages 10-12)

2. Etiology

2.1 Disease causal factors

Genetic cause: Heterozygous loss-of-function (LoF) variants and deletions in EFTUD2 causing haploinsufficiency are the established cause of MFDM. (lines2012haploinsufficiencyofa pages 1-2, lines2012haploinsufficiencyofa pages 4-5, gandomi2015array‐cghisan pages 1-2)

A cohort-defining study concluded: “Taken together, our findings are consistent with de novo haploinsufficiency of EFTUD2 as the cause of MFDM in all cases assessed to date.” (lines2012haploinsufficiencyofa pages 4-5)

2.2 Risk factors

  • Genetic: Pathogenic EFTUD2 variants (de novo most common). (lines2012haploinsufficiencyofa pages 1-2, jacob2020adenovo pages 1-2)
  • Environmental: No MFDM-specific environmental risk factors were identified in the retrieved evidence.

2.3 Protective factors

No protective genetic or environmental factors were identified in the retrieved evidence.

2.4 Gene–environment interactions

No MFDM-specific gene–environment interaction data were identified in the retrieved evidence.

3. Phenotypes

3.1 Core craniofacial and ENT phenotypes (with frequencies where available)

Large phenotype summaries compiled in recent MFDM literature report high-frequency craniofacial/ear manifestations, including: - Micrognathia: 93/95 (98%) (kohailan2022adenovo pages 2-4) - Small/dysplastic pinnae: 90/93 (97%) (kohailan2022adenovo pages 2-4) - Malar hypoplasia: 84/90 (93%) (kohailan2022adenovo pages 2-4) - Microcephaly: 84/95 (88%) (kohailan2022adenovo pages 2-4) - Cleft palate: 45/94 (48%) (kohailan2022adenovo pages 2-4) - Hearing loss: 75/89 (84%), with conductive 33/55 (60%), mixed 15/55 (27%), sensorineural 7/55 (13%) (kohailan2022adenovo pages 2-4) - Auditory canal atresia/stenosis: 50/78 (64%) (kohailan2022adenovo pages 2-4)

In the original 12-person cohort, “Hearing loss, generally conductive, was reported in 10 of the 12 individuals,” and choanal/aural atresia, cleft palate, and congenital heart defects were each present in >50% of individuals. (lines2012haploinsufficiencyofa pages 4-5)

Suggested HPO terms: see ontology mapping table below (artifact-01).

3.2 Neurodevelopmental phenotypes

  • Developmental delay is near-universal in compiled cohorts (e.g., 89/89, 100%). (kohailan2022adenovo pages 2-4)
  • Expressive language is disproportionately affected; in the AJHG cohort, only ~50% attained any speech and first words typically occurred at 20–30 months. (lines2012haploinsufficiencyofa pages 3-4)

3.3 Extracranial phenotypes (examples with quantitative estimates)

Reported extracranial manifestations include: - Congenital heart defects: 29/95 (31%) in a compiled summary (kohailan2022adenovo pages 2-4); in some descriptions, congenital heart disease is ~40% (jacob2020adenovo pages 1-2) - Esophageal atresia: 24/91 (26%) in a compiled summary (kohailan2022adenovo pages 2-4); ~40% in a case-report summary (jacob2020adenovo pages 1-2) - Thumb anomalies: 25/83 (30%) (kohailan2022adenovo pages 2-4) - Epileptic seizures: 23/83 (28%) in a compiled summary (kohailan2022adenovo pages 2-4)

3.4 Onset, severity, progression

MFDM can present congenitally or with postnatal evolution. One cohort summary reports congenital onset in 36/57 (63%) versus postnatal onset in 21/57 (37%). (kohailan2022adenovo pages 2-4)

Microcephaly can be progressive and severe; the original cohort reports head circumference eventually 3–6 SD below the mean in severe/progressive cases. (lines2012haploinsufficiencyofa pages 1-2)

3.5 Imaging and laboratory phenotypes

Brain MRI can be normal or show nonspecific abnormalities; in one small subset of the original cohort, 2/4 MRIs were normal and 2/4 showed delayed myelination or nonspecific white matter changes. (lines2012haploinsufficiencyofa pages 3-4)

3.6 Quality of life impact

Direct, standardized QoL instruments (e.g., SF-36, EQ-5D) were not found in the retrieved MFDM-specific evidence. Functional impacts inferred from the phenotype include hearing impairment, airway/feeding problems, and developmental delay. (gandomi2015array‐cghisan pages 1-2, lines2012haploinsufficiencyofa pages 3-4)

4. Genetic / molecular information

4.1 Causal gene(s)

  • EFTUD2 (OMIM *603892; per case-report literature), encoding spliceosomal GTPase U5-116kD. (chen2024atypicalmandibulofacialdysostosis pages 5-6, jacob2020adenovo pages 1-2)

OpenTargets disease–gene association also identifies EFTUD2 as the sole top target linked to MONDO_0012516, with supporting literature. (OpenTargets Search: mandibulofacial dysostosis with microcephaly)

4.2 Pathogenic variant types and examples

MFDM-associated variants span multiple classes consistent with haploinsufficiency: - Deletions/CNVs (supporting aCGH/CMA utility) (gandomi2015array‐cghisan pages 1-2) - Frameshift/nonsense/splice-site variants in early cohort studies (lines2012haploinsufficiencyofa pages 4-5) - Synonymous splice-disrupting variant demonstrated by RT-PCR showing exon 9 skipping and frameshift/premature stop (jacob2020adenovo pages 1-2) - Functionally verified splice-site variant via minigene assay (lines2012haploinsufficiencyofa pages 4-5)

2024 variant-spectrum expansion: A novel heterozygous frameshifting insertion (c.215_216insT) was reported; the authors state it causes a premature stop and truncation, consistent with LoF. (chen2024atypicalmandibulofacialdysostosis pages 5-6)

4.3 Inheritance, penetrance, mosaicism

Inheritance is autosomal dominant with most cases de novo. Literature summaries note familial transmission occurs in a minority (e.g., ~19%) and germline mosaicism around ~6%. (jacob2020adenovo pages 1-2, chen2024atypicalmandibulofacialdysostosis pages 1-2)

4.4 Modifier genes / epigenetics

No MFDM-specific modifier gene or epigenetic mechanism evidence was identified in the retrieved sources.

5. Environmental information

No MFDM-specific environmental, lifestyle, or infectious contributors were identified in the retrieved evidence.

6. Mechanism / pathophysiology

6.1 Current mechanistic model (causal chain)

Evidence from vertebrate disease models supports the following chain: 1. EFTUD2 haploinsufficiency → impaired U5 snRNP spliceosome function and widespread splicing defects (lines2012haploinsufficiencyofa pages 1-2, beauchamp2021mutationineftud2 pages 1-2) 2. Recurrent mis-splicing of Mdm2 (notably exon 3 skipping) → p53 stabilization/activation (beauchamp2021mutationineftud2 pages 10-12, beauchamp2021mutationineftud2 pages 1-2) 3. p53 activation → apoptosis in neural crest and neural progenitor contexts → depletion of craniofacial precursor cells (beauchamp2021mutationineftud2 pages 10-12, beauchamp2021mutationineftud2 pages 1-2) 4. Depletion/morphogenetic failure → craniofacial malformations and neurodevelopmental abnormalities (beauchamp2021mutationineftud2 pages 10-12, beauchamp2021mutationineftud2 pages 1-2)

A key statement from the Xenopus-focused review summarizes a common theme: “Animal models of NRS and MFDM indicate that MFD results from an early depletion of neural crest progenitors through a mechanism that involves apoptosis.” (park2022thecoresplicing pages 13-14)

6.2 Upstream vs downstream mechanisms

  • Upstream: spliceosome dysfunction / alternative splicing defects (GO:0000398; GO:0000381) (lines2012haploinsufficiencyofa pages 1-2, beauchamp2021mutationineftud2 pages 1-2)
  • Intermediate: p53 pathway activation; intrinsic apoptotic signaling (beauchamp2021mutationineftud2 pages 10-12)
  • Downstream: reduced cranial neural crest cells; impaired craniofacial morphogenesis; microcephaly and developmental delay (beauchamp2021mutationineftud2 pages 10-12, beauchamp2021mutationineftud2 pages 1-2)

6.3 Key cell types and tissues implicated

  • Cranial neural crest cells and neural progenitors are most strongly supported in model systems. (beauchamp2021mutationineftud2 pages 10-12, park2022thecoresplicing pages 13-14)

Suggested CL terms: see artifact-01.

6.4 Therapeutic mechanistic experiments (preclinical)

In a neural-crest-specific Eftud2 mouse model, p53 inhibition with pifithrin-α partially improved craniofacial development; one report noted midbrain improvement in 3/11 treated mutants vs 0/41 untreated (p=0.0139) and increased first pharyngeal arch size (p<0.05). (beauchamp2020missplicingofmdm2 pages 15-19, beauchamp2021mutationineftud2 pages 10-12)

However, genetic Trp53 deletion reduced apoptosis without rescuing craniofacial morphology or survival, supporting additional p53-independent contributions (mis-splicing of other transcripts). (beauchamp2022craniofacialdefectsin pages 1-2, beauchamp2022craniofacialdefectsin pages 10-12)

7. Anatomical structures affected

Primary affected structures include craniofacial skeleton and external/middle ear; choanae and palate are commonly involved, with variable CNS and extracranial organ involvement (heart, esophagus). (gandomi2015array‐cghisan pages 1-2, kohailan2022adenovo pages 2-4)

Suggested UBERON terms: see artifact-01.

8. Temporal development

MFDM is typically congenital or early childhood in presentation, with congenital vs postnatal onset reported (63% vs 37% in one summary). Microcephaly may be congenital or progressive postnatally. (kohailan2022adenovo pages 2-4, lines2012haploinsufficiencyofa pages 1-2)

9. Inheritance and population

9.1 Epidemiology

A 2024 report states MFDM prevalence is <1/1,000,000 and that only approximately 150 cases with EFTUD2 mutations had been reported, acknowledging underestimation. (chen2024atypicalmandibulofacialdysostosis pages 1-2)

A separate 2024 report notes 126 cases reported to date (context-dependent case counting). (lyulchevabennett2024dualdiagnosisof pages 1-2)

9.2 Population demographics

No robust sex ratio, geographic distribution, or founder-effect variants were identified in the retrieved evidence.

10. Diagnostics

10.1 Clinical recognition and differential diagnosis

MFDM may be misdiagnosed due to overlap with other craniofacial dysostoses (e.g., Treacher Collins syndrome, Nager syndrome, oculo-auriculo-vertebral spectrum, and atypical CHARGE). (chen2024atypicalmandibulofacialdysostosis pages 5-6, luquetti2013“mandibulofacialdysostosiswith pages 1-3)

10.2 Genetic testing strategy (real-world implementation)

  • WES/WGS (trio preferred) is repeatedly used to resolve ambiguous craniofacial diagnoses and identify de novo EFTUD2 variants, with Sanger confirmation. (chen2024atypicalmandibulofacialdysostosis pages 5-6, luquetti2013“mandibulofacialdysostosiswith pages 1-3)
  • For splice/synonymous candidates, RNA-level functional validation (RT-PCR) or minigene assays can demonstrate splicing disruption. (jacob2020adenovo pages 1-2, lines2012haploinsufficiencyofa pages 4-5)
  • Array-CGH/CMA can detect EFTUD2 deletions and has been proposed as a first-tier test for EFTUD2-associated MFDM in congenital contexts. (gandomi2015array‐cghisan pages 1-2)

2024 real-world genomics example: A complex EFTUD2 intragenic rearrangement was detected via large-scale genomics programs (DDD and 100,000 Genomes), illustrating structural variant contributions and the utility of genome-wide testing beyond standard single-variant pipelines. (lyulchevabennett2024dualdiagnosisof pages 1-2)

10.3 Imaging and ancillary tests

  • Craniofacial CT may help define zygomatic arch defects; the 2013 series recommended craniofacial CT for zygomatic arch clefting. (luquetti2013“mandibulofacialdysostosiswith pages 1-3)
  • Audiology and ear evaluation are indicated due to high hearing-loss prevalence. (kohailan2022adenovo pages 2-4)

11. Outcome / prognosis

Long-term survival and life expectancy are not well quantified in the retrieved MFDM-specific sources. Severe neonatal airway/feeding problems, congenital heart defects, and esophageal atresia/TEF can drive early morbidity; some individuals survive into adolescence with special education support. (luquetti2013“mandibulofacialdysostosiswith pages 3-4, gandomi2015array‐cghisan pages 1-2)

12. Treatment

MFDM management is primarily supportive and multidisciplinary.

12.1 Supportive and surgical interventions

  • Airway/feeding: Tracheostomy is reported in 11/54 (20%) in a compiled summary; gastrostomy is reported in cohort descriptions and case series tables (without consistently extractable denominators in the retrieved excerpts). (kohailan2022adenovo pages 2-4, lines2012haploinsufficiencyofa pages 3-4)
  • Hearing: High prevalence of conductive/mixed hearing loss supports hearing evaluation and management (e.g., hearing aids, surgical/ENT management), although device/surgery utilization rates were not available in the extracted evidence. (kohailan2022adenovo pages 2-4)
  • Speech/language and developmental supports: Speech therapy and developmental interventions are used in practice (explicitly noted in at least one case report’s workup/management). (kohailan2022adenovo pages 2-4)

12.2 Experimental / mechanism-based approaches (preclinical)

Preclinical work in mouse suggests that reducing p53 activity (e.g., pifithrin-α) can partially rescue craniofacial development, but this is not a clinical therapy and p53 deletion does not fully rescue. (beauchamp2021mutationineftud2 pages 10-12, beauchamp2022craniofacialdefectsin pages 10-12)

12.3 MAXO term suggestions

See artifact-01.

13. Prevention

Primary prevention is not established for MFDM given its genetic etiology. Prevention in practice focuses on: - Genetic counseling for autosomal dominant inheritance with predominant de novo occurrence and the possibility of parental mosaicism. (jacob2020adenovo pages 1-2, chen2024atypicalmandibulofacialdysostosis pages 1-2) - Prenatal/early diagnosis using genome-wide testing (WES/WGS/CMA), especially in fetuses/newborns with suggestive anomalies. (gandomi2015array‐cghisan pages 1-2, chen2024atypicalmandibulofacialdysostosis pages 5-6)

14. Other species / natural disease

No naturally occurring veterinary MFDM analogs were identified in the retrieved evidence.

15. Model organisms

15.1 Zebrafish

Zebrafish eftud2 mutants show abnormal brain development with neuronal apoptosis and transcriptome-wide splicing defects, supporting a neurodevelopmental disease model and a p53-dependent apoptosis mechanism. (beauchamp2020missplicingofmdm2 pages 19-23)

15.2 Mouse

A neural crest-specific conditional Eftud2 deletion model produces craniofacial and brain malformations and lethality and implicates Mdm2 mis-splicing and p53 activation; partial rescue occurs with p53 inhibition. (beauchamp2021mutationineftud2 pages 10-12, beauchamp2022craniofacialdefectsin pages 1-2)

15.3 Xenopus

Knockdown studies of core splicing factors (including eftud2) implicate a requirement for neural crest formation and craniofacial development. (park2022thecoresplicing pages 13-14)

15.4 Model limitations

A simple heterozygous mouse exon 2 deletion line does not recapitulate MFDM well, suggesting the need for tissue-specific or allele-specific modeling strategies. (park2022thecoresplicing pages 13-14)

High-value curated summaries

Category Summary
Disease Mandibulofacial dysostosis with microcephaly (MFDM), also called mandibulofacial dysostosis-microcephaly syndrome / Guion-Almeida type (OpenTargets Search: mandibulofacial dysostosis with microcephaly, lines2012haploinsufficiencyofa pages 1-2, luquetti2013“mandibulofacialdysostosiswith pages 1-3)
Identifiers MONDO: MONDO_0012516; OMIM: 610536 (OpenTargets Search: mandibulofacial dysostosis with microcephaly, chen2024atypicalmandibulofacialdysostosis pages 5-6, luquetti2013“mandibulofacialdysostosiswith pages 1-3)
Causal gene EFTUD2 (elongation factor Tu GTP binding domain containing 2), encoding the U5-116 kD spliceosomal GTPase (OpenTargets Search: mandibulofacial dysostosis with microcephaly, chen2024atypicalmandibulofacialdysostosis pages 5-6, lines2012haploinsufficiencyofa pages 1-2, jacob2020adenovo pages 1-2)
Inheritance Autosomal dominant; most reported cases are de novo heterozygous loss-of-function variants or deletions consistent with haploinsufficiency (lines2012haploinsufficiencyofa pages 1-2, jacob2020adenovo pages 1-2, lines2012haploinsufficiencyofa pages 4-5, gandomi2015array‐cghisan pages 1-2)
Variant spectrum Deletions, frameshift, nonsense, splice-site, missense, start-loss, and synonymous splice-disrupting variants have been reported (jacob2020adenovo pages 1-2, lines2012haploinsufficiencyofa pages 4-5)
Core craniofacial features Mandibular and maxillary hypoplasia, micrognathia, microtia/external ear anomalies, choanal atresia, cleft palate, characteristic dysmorphism (luquetti2013“mandibulofacialdysostosiswith pages 3-4, lines2012haploinsufficiencyofa pages 1-2, lines2012haploinsufficiencyofa pages 4-5, gandomi2015array‐cghisan pages 1-2, luquetti2013“mandibulofacialdysostosiswith pages 1-3)
Neurodevelopmental features Microcephaly, developmental delay / intellectual disability, delayed psychomotor milestones; microcephaly may be congenital or postnatal and can become severe/progressive (luquetti2013“mandibulofacialdysostosiswith pages 3-4, lines2012haploinsufficiencyofa pages 1-2, jacob2020adenovo pages 1-2)
Quantitative clinical findings Choanal/aural atresia, cleft palate, and congenital heart defects each reported in >50% of affected individuals in the original 12-person cohort; hearing loss in 10/12; head circumference eventually 3–6 SD below the mean in severe/progressive cases (lines2012haploinsufficiencyofa pages 1-2, lines2012haploinsufficiencyofa pages 4-5)
Extracranial findings Esophageal atresia ~40%, congenital heart disease ~40%, thumb abnormalities ~25%, short stature in ~1/3; feeding/airway problems and abnormal brain myelination/white matter changes also reported (jacob2020adenovo pages 1-2, gandomi2015array‐cghisan pages 1-2)
Diagnostic approach Clinical suspicion based on craniofacial pattern plus microcephaly/developmental delay; molecular confirmation by WES/WGS or trio exome; Sanger confirmation; RNA studies/minigene assays for splice variants; aCGH/CMA can detect pathogenic EFTUD2 deletions and has been proposed as a first-tier test in some congenital presentations (chen2024atypicalmandibulofacialdysostosis pages 5-6, jacob2020adenovo pages 1-2, gandomi2015array‐cghisan pages 1-2, luquetti2013“mandibulofacialdysostosiswith pages 1-3)
Differential diagnosis clues Phenotypic overlap with Treacher Collins syndrome, Nager syndrome, oculoauriculovertebral spectrum, and atypical CHARGE syndrome can delay diagnosis (chen2024atypicalmandibulofacialdysostosis pages 5-6, luquetti2013“mandibulofacialdysostosiswith pages 1-3)
Mechanistic chain EFTUD2 haploinsufficiency → impaired U5 spliceosome function / transcriptome-wide splicing defects → increased exon skipping including Mdm2 exon 3 skipping → p53 stabilization/activation → apoptosis of neural crest and neural progenitor cells → depletion of craniofacial precursor cells → craniofacial malformations and microcephaly (beauchamp2020missplicingofmdm2 pages 15-19, beauchamp2022craniofacialdefectsin pages 1-2, beauchamp2020missplicingofmdm2 pages 19-23, beauchamp2020missplicingofmdm2 pages 1-5, beauchamp2021mutationineftud2 pages 10-12, beauchamp2021mutationineftud2 pages 1-2)
Affected developmental cell populations Cranial neural crest cells and neural progenitors are the best-supported vulnerable populations in model systems (park2022thecoresplicing pages 13-14, beauchamp2020missplicingofmdm2 pages 15-19, beauchamp2022craniofacialdefectsin pages 1-2, beauchamp2021mutationineftud2 pages 10-12)
Model-organism evidence Zebrafish eftud2 mutants show abnormal brain development and p53-dependent apoptosis; neural-crest-specific mouse Eftud2 loss causes brain/craniofacial malformations and prenatal lethality; Xenopus knockdown supports a neural crest/craniofacial developmental requirement (park2022thecoresplicing pages 13-14, beauchamp2020missplicingofmdm2 pages 19-23, beauchamp2020missplicingofmdm2 pages 1-5, beauchamp2021mutationineftud2 pages 10-12)
Rescue evidence Pharmacologic p53 inhibition with pifithrin-α partially improved morphology in the mouse model: midbrain improvement in 3/11 treated mutants vs 0/41 untreated; first pharyngeal arch size increased significantly (p<0.05). However, Trp53 deletion reduced apoptosis without fully rescuing craniofacial defects or survival, indicating additional p53-independent mis-splicing mechanisms (beauchamp2020missplicingofmdm2 pages 15-19, beauchamp2022craniofacialdefectsin pages 1-2, beauchamp2021mutationineftud2 pages 10-12, beauchamp2022craniofacialdefectsin pages 10-12)
Current understanding MFDM is best understood as an EFTUD2-related craniofacial spliceosomopathy with dominant loss-of-function, variable expressivity, and disease mechanisms centered on selective developmental vulnerability of cranial neural crest and neuroepithelial lineages (lines2012haploinsufficiencyofa pages 1-2, park2022thecoresplicing pages 13-14, beauchamp2022craniofacialdefectsin pages 1-2, beauchamp2021mutationineftud2 pages 1-2)

Table: This table condenses the main identifiers, genetics, clinical spectrum, diagnostic approaches, and disease mechanism for EFTUD2-related mandibulofacial dysostosis with microcephaly. It is useful as a quick-reference scaffold for a fuller disease knowledge base entry.

Section Item Suggested ontology term(s) Notes/frequency
Phenotype Microcephaly Microcephaly (HP:0000252) Common and often severe/progressive; reported in 84/95 (88%), with congenital or postnatal onset in reported cohorts
Phenotype Micrognathia / mandibular hypoplasia Micrognathia (HP:0000347); Mandibular hypoplasia (HP:0000347) Very common; micrognathia 93/95 (98%) in one summary cohort
Phenotype Malar hypoplasia Malar flattening (HP:0000272) Common; 84/90 (93%) in one summary cohort
Phenotype Microtia / dysplastic external ears Microtia (HP:0008551); Abnormality of the pinna (HP:0000377); Dysplastic pinna (HP:0008553) Very common; small/dysplastic pinnae 90/93 (97%)
Phenotype Preauricular tags Preauricular skin tag (HP:0000384) Recurrent ear-associated feature
Phenotype Hearing loss Hearing impairment (HP:0000365); Conductive hearing impairment (HP:0000405); Mixed hearing impairment (HP:0000408); Sensorineural hearing impairment (HP:0000407) Common; hearing loss 75/89 (84%); conductive predominates
Phenotype Auditory canal stenosis / atresia External auditory canal stenosis (HP:0000400); External auditory canal atresia (HP:0000413) Frequent; auditory atresia/stenosis 50/78 (64%)
Phenotype Choanal atresia Choanal atresia (HP:0000453) Recurrent major craniofacial finding
Phenotype Cleft palate Cleft palate (HP:0000175) Common; 45/94 (48%) in one cohort summary
Phenotype Cleft zygomatic arch / zygomatic defect Abnormal zygomatic bone morphology (HP:0011327) Expanded phenotype; CT can show unilateral or bilateral zygomatic arch clefting
Phenotype Maxillary hypoplasia / midface hypoplasia Maxillary hypoplasia (HP:0000327); Midface retrusion (HP:0011800) Recurrent craniofacial feature
Phenotype Global developmental delay Global developmental delay (HP:0001263) Very common; developmental delay reported in essentially all compiled cases
Phenotype Intellectual disability Intellectual disability (HP:0001249) Common; severity variable
Phenotype Speech delay / expressive language delay Delayed speech and language development (HP:0000750); Expressive language delay (HP:0002474) Common; first words often at 20–30 months
Phenotype Motor delay Delayed gross motor development (HP:0002194) Common; delayed walking/sitting reported
Phenotype Seizures Seizure (HP:0001250) Reported in subsets; 23/83 (28%) in one summary cohort
Phenotype Congenital heart defect Congenital heart malformation (HP:0001627); Atrial septal defect (HP:0001631) Recurrent extracranial feature; ~31% in one summary cohort
Phenotype Esophageal atresia / tracheoesophageal anomaly Esophageal atresia (HP:0002031); Tracheoesophageal fistula (HP:0002575) Recurrent extracranial feature; esophageal atresia 24/91 (26%)
Phenotype Thumb anomalies Abnormal thumb morphology (HP:0009609); Triphalangeal thumb (HP:0001199); Proximally placed thumb (HP:0009623) Reported in subsets; ~25–30%
Phenotype Short stature / growth delay Short stature (HP:0004322); Postnatal growth retardation (HP:0008897) Reported in about one-third in some summaries
Phenotype Feeding difficulty / dysphagia Feeding difficulties (HP:0011968); Dysphagia (HP:0002015) Common in severe neonatal cases; may accompany Pierre Robin sequence or EA/TEF
Phenotype Delayed myelination Delayed CNS myelination (HP:0012447) Seen on MRI in a subset
Phenotype White matter abnormality Abnormality of cerebral white matter (HP:0002500) Nonspecific white matter changes reported on MRI
Phenotype Ventricular enlargement Ventriculomegaly (HP:0002119) Mild posterior lateral ventricular dilation reported in some cases
Phenotype Epibulbar dermoid Epibulbar dermoid (HP:0001140) Expanded phenotype; reported in individual cases
Mechanism Pre-mRNA splicing defect mRNA splicing, via spliceosome (GO:0000398) Core upstream disease mechanism
Mechanism Alternative splicing dysregulation Regulation of alternative mRNA splicing, via spliceosome (GO:0000381) Includes exon skipping events such as Mdm2 exon 3 skipping
Mechanism Neural crest development defect Neural crest cell development (GO:0014032); Neural crest cell migration (GO:0001755) Best-supported developmental cell-population vulnerability
Mechanism Apoptotic cell death Apoptotic process (GO:0006915); Intrinsic apoptotic signaling pathway (GO:0097193) Increased in neural crest/neural progenitor contexts
Mechanism p53 pathway activation Signal transduction by p53 class mediator (GO:0072331); Regulation of transcription by p53 class mediator (GO:0072332) Supported by mouse and zebrafish mechanistic studies
Mechanism Craniofacial morphogenesis defect Craniofacial skeletal system development (GO:1904888); Branchiomeric skeletal muscle development / pharyngeal arch development-related annotation Downstream morphogenetic consequence
Mechanism Neurodevelopmental defect Brain development (GO:0007420); Forebrain development (GO:0030900) Relevant to microcephaly and developmental delay
Cell type Cranial neural crest cells Neural crest cell (CL:0000007); Cranial neural crest cell (CL:0002320) Strongest disease-relevant cell population from models
Cell type Neural progenitor cells Neural progenitor cell (CL:0000047) Supported by zebrafish and brain-development studies
Cell type Neuroepithelial cells Neuroepithelial cell (CL:0000644) Relevant to early CNS development
Cell type Chondrocytes Chondrocyte (CL:0000138) Relevant to craniofacial cartilage development
Cell type Osteoblast lineage cells Osteoblast (CL:0000062) Relevant to mandibular/zygomatic/maxillary hypoplasia
Anatomy Mandible mandible (UBERON:0001684) Primary craniofacial skeletal site
Anatomy Maxilla maxilla (UBERON:0001685) Primary craniofacial skeletal site
Anatomy Zygomatic bone / arch zygomatic bone (UBERON:0001687) Site of clefting/hypoplasia in some patients
Anatomy External ear / pinna external ear (UBERON:0001032); pinna (UBERON:0001691) Major affected structure
Anatomy External auditory canal external auditory canal (UBERON:0000912) Frequent stenosis/atresia
Anatomy Choana choana (UBERON:0001719) Choanal atresia site
Anatomy Palate secondary palate (UBERON:0001708) Cleft palate site
Anatomy Brain / cerebral white matter brain (UBERON:0000955); cerebral white matter (UBERON:0002316) Relevant to microcephaly, delayed myelination, white matter abnormalities
Anatomy Esophagus esophagus (UBERON:0001043) Relevant to esophageal atresia
Anatomy Heart / atrial septum heart (UBERON:0000948); atrial septum (UBERON:0002085) Relevant to congenital heart disease/ASD
Treatment/management Tracheostomy tracheostomy (MAXO:0000128) Reported in severe airway cases; 11/54 (20%) in one cohort summary
Treatment/management Gastrostomy / feeding tube support gastrostomy (MAXO:0000126); enteral tube feeding (MAXO:0000106) Used in severe feeding/airway cases
Treatment/management Hearing support hearing aid use (MAXO:0000058) Reasonable management action for conductive/mixed hearing loss
Treatment/management Speech therapy speech therapy (MAXO:0000016) Common supportive intervention for expressive language delay
Treatment/management Genetic testing sequence analysis (MAXO:0000147); exome sequencing (MAXO:0000137); genome sequencing (MAXO:0000138); chromosomal microarray analysis (MAXO:0000014) Core diagnostic/management action in modern care pathways
Treatment/management Airway support airway management (MAXO:0000112) Relevant for choanal atresia, glossoptosis, neonatal respiratory compromise
Treatment/management Feeding support feeding therapy (MAXO:0000104); nutritional supplementation/support (MAXO:0000105) Relevant for dysphagia and poor suck/swallow coordination
Treatment/management Craniofacial surgery craniofacial surgical intervention (MAXO:0001173) Disease-specific reconstructive needs may arise; evidence is case-based
Treatment/management Cardiac evaluation/intervention cardiology evaluation/intervention (MAXO term family) Supportive management for CHD/ASD
Treatment/management Experimental p53 inhibition small molecule inhibitor treatment (MAXO:0000013) Preclinical only; pifithrin-α partially rescued mouse craniofacial phenotype

Table: This table maps evidence-based mandibulofacial dysostosis with microcephaly features to suggested ontology terms across HPO, GO, CL, UBERON, and MAXO. It is useful as a knowledge-base curation scaffold for phenotype, mechanism, anatomy, cell type, and management annotations. (lines2012haploinsufficiencyofa pages 1-2, lines2012haploinsufficiencyofa pages 4-5, park2022thecoresplicing pages 13-14, beauchamp2022craniofacialdefectsin pages 1-2, chen2024atypicalmandibulofacialdysostosis pages 1-2, lyulchevabennett2024dualdiagnosisof pages 1-2, gandomi2015array‐cghisan pages 1-2, kohailan2022adenovo pages 2-4, lines2012haploinsufficiencyofa pages 3-4)

Recent developments (2023–2024) and real-world implementations

  • 2024 variant expansion and updated epidemiology: A 2024 MFDM case report emphasizes rarity (prevalence <1/1,000,000) and ~150 molecularly confirmed cases, and reports a new pathogenic EFTUD2 frameshift insertion detected by WES. (Apr 2024; https://doi.org/10.1002/mgg3.2426) (chen2024atypicalmandibulofacialdysostosis pages 1-2, chen2024atypicalmandibulofacialdysostosis pages 5-6)
  • 2024 structural variant detection via national genome projects: A 2024 report demonstrates that WGS in large-scale genomics programs (DDD, 100,000 Genomes) can detect complex intragenic EFTUD2 rearrangements, supporting the adoption of SV-aware pipelines when MFDM is suspected. (Sep 2024; https://doi.org/10.1186/s12920-024-01999-0) (lyulchevabennett2024dualdiagnosisof pages 1-2)

Expert opinion / analysis (from authoritative sources in this evidence set)

  • The cohort-defining AJHG study positioned MFDM as the first multiple-malformation syndrome attributed to a defect of the major spliceosome and established the haploinsufficiency mechanism for EFTUD2 in MFDM. (Feb 2012; https://doi.org/10.1016/j.ajhg.2011.12.023) (lines2012haploinsufficiencyofa pages 1-2, lines2012haploinsufficiencyofa pages 4-5)
  • Mechanistic mouse work proposes a testable causal link from Mdm2 mis-splicing to p53 overactivation and neural crest apoptosis and demonstrates partial phenotypic rescue by p53 inhibition, but also indicates additional p53-independent contributions to lethality and malformations. (Feb 2021; https://doi.org/10.1093/hmg/ddab051; Aug 2022; https://doi.org/10.3390/ijms23169033) (beauchamp2021mutationineftud2 pages 10-12, beauchamp2022craniofacialdefectsin pages 1-2)

Key limitations of this report (evidence gaps)

  • This run could not retrieve Orphanet/MeSH/ICD codes, ClinVar allele frequencies, or formal clinical practice guidelines.
  • Robust long-term survival/life expectancy statistics and standardized QoL measurements were not found in the retrieved MFDM-specific literature.
  • No MFDM-specific interventional clinical trials were identified in ClinicalTrials.gov via available tools.

References

  1. (lines2012haploinsufficiencyofa pages 1-2): Matthew A. Lines, Lijia Huang, Jeremy Schwartzentruber, Stuart L. Douglas, Danielle C. Lynch, Chandree Beaulieu, Maria Leine Guion-Almeida, Roseli Maria Zechi-Ceide, Blanca Gener, Gabriele Gillessen-Kaesbach, Caroline Nava, Geneviève Baujat, Denise Horn, Usha Kini, Almuth Caliebe, Yasemin Alanay, Gulen Eda Utine, Dorit Lev, Jürgen Kohlhase, Arthur W. Grix, Dietmar R. Lohmann, Ute Hehr, Detlef Böhm, Jacek Majewski, Dennis E. Bulman, Dagmar Wieczorek, and Kym M. Boycott. Haploinsufficiency of a spliceosomal gtpase encoded by eftud2 causes mandibulofacial dysostosis with microcephaly. American journal of human genetics, 90 2:369-77, Feb 2012. URL: https://doi.org/10.1016/j.ajhg.2011.12.023, doi:10.1016/j.ajhg.2011.12.023. This article has 252 citations and is from a highest quality peer-reviewed journal.

  2. (lines2012haploinsufficiencyofa pages 4-5): Matthew A. Lines, Lijia Huang, Jeremy Schwartzentruber, Stuart L. Douglas, Danielle C. Lynch, Chandree Beaulieu, Maria Leine Guion-Almeida, Roseli Maria Zechi-Ceide, Blanca Gener, Gabriele Gillessen-Kaesbach, Caroline Nava, Geneviève Baujat, Denise Horn, Usha Kini, Almuth Caliebe, Yasemin Alanay, Gulen Eda Utine, Dorit Lev, Jürgen Kohlhase, Arthur W. Grix, Dietmar R. Lohmann, Ute Hehr, Detlef Böhm, Jacek Majewski, Dennis E. Bulman, Dagmar Wieczorek, and Kym M. Boycott. Haploinsufficiency of a spliceosomal gtpase encoded by eftud2 causes mandibulofacial dysostosis with microcephaly. American journal of human genetics, 90 2:369-77, Feb 2012. URL: https://doi.org/10.1016/j.ajhg.2011.12.023, doi:10.1016/j.ajhg.2011.12.023. This article has 252 citations and is from a highest quality peer-reviewed journal.

  3. (beauchamp2022craniofacialdefectsin pages 1-2): Marie-Claude Beauchamp, Alexia Boucher, Yanchen Dong, Rachel Aber, and Loydie A. Jerome-Majewska. Craniofacial defects in embryos with homozygous deletion of eftud2 in their neural crest cells are not rescued by trp53 deletion. International Journal of Molecular Sciences, 23:9033, Aug 2022. URL: https://doi.org/10.3390/ijms23169033, doi:10.3390/ijms23169033. This article has 13 citations.

  4. (beauchamp2021mutationineftud2 pages 10-12): Marie-Claude Beauchamp, Anissa Djedid, Eric Bareke, Fjodor Merkuri, Rachel Aber, Annie S Tam, Matthew A Lines, Kym M Boycott, Peter C Stirling, Jennifer L Fish, Jacek Majewski, and Loydie A Jerome-Majewska. Mutation in eftud2 causes craniofacial defects in mice via mis-splicing of mdm2 and increased p53. Human molecular genetics, 30:739-757, Feb 2021. URL: https://doi.org/10.1093/hmg/ddab051, doi:10.1093/hmg/ddab051. This article has 41 citations and is from a domain leading peer-reviewed journal.

  5. (chen2024atypicalmandibulofacialdysostosis pages 1-2): Ying Chen, Run Yang, Xin Chen, Naier Lin, Chenlong Li, Yaoyao Fu, Aijuan He, Yimin Wang, Tianyu Zhang, and Jing Ma. Atypical mandibulofacial dysostosis with microcephaly diagnosed through the identification of a novel pathogenic mutation in eftud2. Molecular Genetics & Genomic Medicine, Apr 2024. URL: https://doi.org/10.1002/mgg3.2426, doi:10.1002/mgg3.2426. This article has 6 citations and is from a peer-reviewed journal.

  6. (luquetti2013“mandibulofacialdysostosiswith pages 1-3): Daniela V. Luquetti, Anne V. Hing, Mark J. Rieder, Deborah A. Nickerson, Emily H. Turner, Joshua Smith, Sarah Park, and Michael L. Cunningham. “mandibulofacial dysostosis with microcephaly” caused by eftud2 mutations: expanding the phenotype. American Journal of Medical Genetics Part A, 161:108-113, Jan 2013. URL: https://doi.org/10.1002/ajmg.a.35696, doi:10.1002/ajmg.a.35696. This article has 90 citations.

  7. (OpenTargets Search: mandibulofacial dysostosis with microcephaly): Open Targets Query (mandibulofacial dysostosis with microcephaly, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  8. (chen2024atypicalmandibulofacialdysostosis pages 5-6): Ying Chen, Run Yang, Xin Chen, Naier Lin, Chenlong Li, Yaoyao Fu, Aijuan He, Yimin Wang, Tianyu Zhang, and Jing Ma. Atypical mandibulofacial dysostosis with microcephaly diagnosed through the identification of a novel pathogenic mutation in eftud2. Molecular Genetics & Genomic Medicine, Apr 2024. URL: https://doi.org/10.1002/mgg3.2426, doi:10.1002/mgg3.2426. This article has 6 citations and is from a peer-reviewed journal.

  9. (beauchamp2020missplicingofmdm2 pages 19-23): Marie-Claude Beauchamp, Anissa Djedid, Eric Bareke, Fjodor Merkuri, Rachel Aber, Annie S. Tam, Matthew A. Lines, Kym M. Boycott, Peter C. Stirling, Jennifer L. Fish, Jacek Majewski, and Loydie A. Jerome-Majewska. Mis-splicing of mdm2 leads to increased p53-activity and craniofacial defects in a mfdm eftud2 mutant mouse model. bioRxiv, Sep 2020. URL: https://doi.org/10.1101/2020.09.22.308205, doi:10.1101/2020.09.22.308205. This article has 1 citations.

  10. (park2022thecoresplicing pages 13-14): Byung-Yong Park, Melanie Tachi-Duprat, Chibuike Ihewulezi, Arun Devotta, and Jean-Pierre Saint-Jeannet. The core splicing factors eftud2, snrpb and txnl4a are essential for neural crest and craniofacial development. Journal of Developmental Biology, 10:29, Jul 2022. URL: https://doi.org/10.3390/jdb10030029, doi:10.3390/jdb10030029. This article has 26 citations.

  11. (kohailan2022adenovo pages 2-4): Muhammad Kohailan, Omayma Al-Saei, Sujitha Padmajeya, Waleed Aamer, Najwa Elbashir, Ammira Al-Shabeeb Akil, Abdul-Rauf Kamboh, and Khalid Fakhro. A de novo start-loss in eftud2 associated with mandibulofacial dysostosis with microcephaly: case report. Cold Spring Harbor Molecular Case Studies, 8:a006206, Jun 2022. URL: https://doi.org/10.1101/mcs.a006206, doi:10.1101/mcs.a006206. This article has 7 citations and is from a peer-reviewed journal.

  12. (gandomi2015array‐cghisan pages 1-2): S.K. Gandomi, M. Parra, D. Reeves, V. Yap, and C.‐L. Gau. Array‐cgh is an effective first‐tier diagnostic test for eftud2‐associated congenital mandibulofacial dysostosis with microcephaly. Clinical Genetics, 87:80-84, Jan 2015. URL: https://doi.org/10.1111/cge.12328, doi:10.1111/cge.12328. This article has 27 citations and is from a peer-reviewed journal.

  13. (jacob2020adenovo pages 1-2): Arthur Jacob, Jennifer Pasquier, Raphael Carapito, Frédéric Auradé, Anne Molitor, Philippe Froguel, Khalid Fakhro, Najeeb Halabi, Géraldine Viot, Seiamak Bahram, and Arash Rafii. A de novo synonymous variant in eftud2 disrupts normal splicing and causes mandibulofacial dysostosis with microcephaly: case report. BMC Medical Genetics, Sep 2020. URL: https://doi.org/10.1186/s12881-020-01121-y, doi:10.1186/s12881-020-01121-y. This article has 16 citations and is from a peer-reviewed journal.

  14. (lines2012haploinsufficiencyofa pages 3-4): Matthew A. Lines, Lijia Huang, Jeremy Schwartzentruber, Stuart L. Douglas, Danielle C. Lynch, Chandree Beaulieu, Maria Leine Guion-Almeida, Roseli Maria Zechi-Ceide, Blanca Gener, Gabriele Gillessen-Kaesbach, Caroline Nava, Geneviève Baujat, Denise Horn, Usha Kini, Almuth Caliebe, Yasemin Alanay, Gulen Eda Utine, Dorit Lev, Jürgen Kohlhase, Arthur W. Grix, Dietmar R. Lohmann, Ute Hehr, Detlef Böhm, Jacek Majewski, Dennis E. Bulman, Dagmar Wieczorek, and Kym M. Boycott. Haploinsufficiency of a spliceosomal gtpase encoded by eftud2 causes mandibulofacial dysostosis with microcephaly. American journal of human genetics, 90 2:369-77, Feb 2012. URL: https://doi.org/10.1016/j.ajhg.2011.12.023, doi:10.1016/j.ajhg.2011.12.023. This article has 252 citations and is from a highest quality peer-reviewed journal.

  15. (beauchamp2021mutationineftud2 pages 1-2): Marie-Claude Beauchamp, Anissa Djedid, Eric Bareke, Fjodor Merkuri, Rachel Aber, Annie S Tam, Matthew A Lines, Kym M Boycott, Peter C Stirling, Jennifer L Fish, Jacek Majewski, and Loydie A Jerome-Majewska. Mutation in eftud2 causes craniofacial defects in mice via mis-splicing of mdm2 and increased p53. Human molecular genetics, 30:739-757, Feb 2021. URL: https://doi.org/10.1093/hmg/ddab051, doi:10.1093/hmg/ddab051. This article has 41 citations and is from a domain leading peer-reviewed journal.

  16. (beauchamp2020missplicingofmdm2 pages 15-19): Marie-Claude Beauchamp, Anissa Djedid, Eric Bareke, Fjodor Merkuri, Rachel Aber, Annie S. Tam, Matthew A. Lines, Kym M. Boycott, Peter C. Stirling, Jennifer L. Fish, Jacek Majewski, and Loydie A. Jerome-Majewska. Mis-splicing of mdm2 leads to increased p53-activity and craniofacial defects in a mfdm eftud2 mutant mouse model. bioRxiv, Sep 2020. URL: https://doi.org/10.1101/2020.09.22.308205, doi:10.1101/2020.09.22.308205. This article has 1 citations.

  17. (beauchamp2022craniofacialdefectsin pages 10-12): Marie-Claude Beauchamp, Alexia Boucher, Yanchen Dong, Rachel Aber, and Loydie A. Jerome-Majewska. Craniofacial defects in embryos with homozygous deletion of eftud2 in their neural crest cells are not rescued by trp53 deletion. International Journal of Molecular Sciences, 23:9033, Aug 2022. URL: https://doi.org/10.3390/ijms23169033, doi:10.3390/ijms23169033. This article has 13 citations.

  18. (lyulchevabennett2024dualdiagnosisof pages 1-2): Ekaterina Lyulcheva-Bennett, Christopher Kershaw, Eleanor Baker, Stuart Gillies, Emma McCarthy, Jenny Higgs, Natalie Canham, Dawn Hennigan, Chris Parks, and Daimark Bennett. Dual diagnosis of achondroplasia and mandibulofacial dysostosis with microcephaly. BMC Medical Genomics, Sep 2024. URL: https://doi.org/10.1186/s12920-024-01999-0, doi:10.1186/s12920-024-01999-0. This article has 4 citations and is from a peer-reviewed journal.

  19. (luquetti2013“mandibulofacialdysostosiswith pages 3-4): Daniela V. Luquetti, Anne V. Hing, Mark J. Rieder, Deborah A. Nickerson, Emily H. Turner, Joshua Smith, Sarah Park, and Michael L. Cunningham. “mandibulofacial dysostosis with microcephaly” caused by eftud2 mutations: expanding the phenotype. American Journal of Medical Genetics Part A, 161:108-113, Jan 2013. URL: https://doi.org/10.1002/ajmg.a.35696, doi:10.1002/ajmg.a.35696. This article has 90 citations.

  20. (beauchamp2020missplicingofmdm2 pages 1-5): Marie-Claude Beauchamp, Anissa Djedid, Eric Bareke, Fjodor Merkuri, Rachel Aber, Annie S. Tam, Matthew A. Lines, Kym M. Boycott, Peter C. Stirling, Jennifer L. Fish, Jacek Majewski, and Loydie A. Jerome-Majewska. Mis-splicing of mdm2 leads to increased p53-activity and craniofacial defects in a mfdm eftud2 mutant mouse model. bioRxiv, Sep 2020. URL: https://doi.org/10.1101/2020.09.22.308205, doi:10.1101/2020.09.22.308205. This article has 1 citations.

Artifacts